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Abstract
Background: Telephone quit lines are accessible to many smokers and are used to engage
motivated smokers to make quit attempts. Smoking cessation counselling provided via telephone
can either be reactive (i.e. primarily involving the provision of evidence-based information), or
proactive (i.e. primarily involving repeated, sequenced calls from and interaction with trained
cessation counsellors). Some studies have found proactive telephone counselling more effective
and this trial will investigate whether or not proactive telephone support for smoking cessation,
delivered through the National Health Service (NHS) Smoking Helpline is more effective or cost-
effective than reactive support. It will also investigate whether or not providing nicotine
replacement therapy (NRT), in addition to telephone counselling, has an adjunctive impact on
smoking cessation rates and whether or not this is cost effective.
Methods: This will be a parallel group, factorial design RCT, conducted through the English
national NHS Smoking Helpline which is run from headquarters in Glasgow. Participants will be
smokers who call the helpline from any location in England and who wish to stop smoking. If 644
participants are recruited to four equally-sized trial groups (total sample size = 2576), the trial will
have 90% power for detecting a treatment effect (Odds Ratio) of 1.5 for each of the two
interventions: i) proactive versus reactive support and ii) the offer of NRT versus no offer. The
primary outcome measure for the study is self-reported, prolonged abstinence from smoking for
at least six months following an agreed quit date. A concurrent health economic evaluation will
investigate the cost effectiveness of the two interventions when delivered via a telephone helpline.
Discussion:  The  PORTSSS  trial will provide high quality evidence to determine the most
appropriate kind of counselling which should be provided via the NHS Smoking Helpline and also
whether or not an additional offer of cost-free NRT is effective and cost effective for smoking
cessation.
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Background
Smoking remains a massive public health problem in the
UK and, for example, is the single most important avoid-
able cause of cancer, responsible for an estimated 45,000
cancer deaths, and 110,000 hospital admissions in the UK
each year.[1] Smoking prevalence is strongly associated
with social disadvantage[1,2] and is the largest identified
cause of social inequalities in health.[2] Consequently,
any reductions in smoking prevalence will result in sub-
stantial population health gain. Comprehensive, popula-
tion-level tobacco control measures, such as the
California Tobacco Control Program are likely to have the
greatest impact on smoking prevalence[3] because the
interventions included in this kind of programme reach
vast numbers of smokers; presumably prompting them to
attempt cessation. However, the provision of effective
smoking cessation interventions to smokers making quit
attempts remains important, because smokers have a
much higher probability of achieving permanent absti-
nence when they benefit from evidence-based smoking
cessation interventions to assist their efforts to stop.
In England, smokers can be supported during quit
attempts by general practitioners: GPs' brief advice against
smoking is effective[4] and GPs can prescribe proven nic-
otine addiction treatments like nicotine replacement ther-
apy (NRT)[5], bupropion[6] and varenicline.[7]
Additionally, smokers who are particularly motivated to
stop can attend NHS Stop Smoking Services (NHSSS)[8]
where they can access effective group[9] or individual[10]
behavioural support. Many NHSSS issue vouchers for
NRT which smokers can then redeem from pharmacies
and others issue NRT directly to patients, without pre-
scription from a doctor, via Patient Group Directives.
Unfortunately, opportunities to deliver effective interven-
tions to smokers are frequently missed in primary
care[11] and, from a population perspective, relatively
few smokers actually attend NHSSS.[12] It is logical,
therefore, to develop alternative methods for supporting
smokers in quit attempts and the provision of telephone
counselling support to smokers who contact quitlines is
one such method.[13]
Clearly, the provision of proactive telephone counselling
could be an effective, additional smoking cessation inter-
vention to use within an overall programme of tobacco
control measures. The considerable accessibility and
'reach' of a national quitline delivering such counselling
should have a demonstrable impact on callers' cessation
rates and could even have an impact on national smoking
prevalence (though this should not be an expected out-
come of introducing one). Additionally, the effectiveness
of quitlines for promoting smoking cessation would be
enhanced if quitline callers could be encouraged to use
established, effective and safe smoking cessation treat-
ments like NRT. In England, a reactive support package
called the 'Together Programme' is provided to smokers
who contact a national quitline called the NHS Smoking
Helpline and, in 2008, proactive support is to be added as
an option to help quitline callers to stop smoking. Addi-
tionally, to augment the effectiveness of counselling
alone, the quitline plans to begin offering cost-free NRT to
callers for whom this is appropriate.[14] NRT is particu-
larly appropriate for use in this way as 100+ trials con-
ducted world wide have demonstrated its undisputed
safety and efficacy, even when used without guidance and
advice from a health professional.[15] Consequently,
some NRT formulations have a licence for general sale
(GSL) in the UK, so they can be retailed outside of phar-
macies.
This trial will, therefore, determine for smokers who call
the NHS Smoking Helpline, whether or not proactive tel-
ephone counselling is more effective or cost effective for
smoking cessation when compared to reactive counsel-
ling. Additionally, it will investigate whether or not offer-
ing quitline callers a voucher for a cost free supply of NRT,
compared to merely advising them to obtain drug treat-
ment for nicotine addiction augments quit rates from
behavioural interventions alone. The influence of eco-
nomic deprivation on the effectiveness of interventions
will be investigated to assess the potential for trial inter-
ventions to impact on smoking-related health inequali-
ties.
Aim
To determine whether or not proactive telephone support
for smoking cessation delivered to quitline callers is more
effective and cost effective than standard 'reactive' provi-
sion and whether or not the offer of a voucher for free NRT
has any additional impact on smoking cessation rates
achieved by behavioural interventions.
Objectives
1. To compare, amongst motivated callers to the NHS
Smoking Helpline, the effectiveness and cost effectiveness
of reactive and proactive quitline care for smoking cessa-
tion.
2. To compare, amongst motivated callers to the NHS
Smoking Helpline, the effectiveness and cost effectiveness
of, in addition to telephone behavioural counselling, two
strategies for making NRT available: i) offering a voucher
for free provision and ii) advising nicotine addiction treat-
ment.
3. To investigate whether or not the provision of tele-
phone counselling for smoking cessation via the NHS
Smoking Helpline is more or less effective for disadvan-
taged smokers.Trials 2009, 10:26 http://www.trialsjournal.com/content/10/1/26
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4. To document uptake of telephone counselling and
offered NRT in trial arms.
Methods/Design
Ethical approval for the study was granted on behalf of the
National Research Ethics Service by Leicestershire, North-
amptonshire & Rutland Research Ethics Committee. This
is a four group, parallel, factorial randomised controlled
trial with investigators blinded to participants' treatment
allocation. Figure 1 summarises the trial design.
Duration of the Trial and Participant Involvement
The trial will recruit participants for approximately 6
months, with the final length of the recruitment period
dependant on the actual recruitment rate. The trial will
close after the final follow up of the last recruit to the
study at 6 months after (s)he is enrolled. The total dura-
tion of the study is, thus, approximately one year.
Enrolled participants will agree a quit date for stopping
smoking and will be allocated to one of the four trial
groups described above/below. More complete details of
trial interventions follow later:
1. Usual telephone support with smoking cessation
(the 'Together Programme')
2. As per group 1 plus additional proactive telephone
support
3. As per group 1 plus the offer of a voucher for free
NRT
4. As per group 2, plus the offer of a voucher for free
NRT
Follow up data will be collected during telephone inter-
views at one and six months after the agreed quit date.
Participants who report smoking cessation at final follow
up (estimated 10% in total) will be asked to provide an
exhaled air carbon monoxide (CO) reading for biochem-
ical verification of smoking status.
Primary Outcome Measure
Self-reported, prolonged abstinence from smoking
between a quit date and 6 months afterwards.
To demonstrate prolongedabstinence, a participant must
report not smoking at the 6 month point, but may admit
to minor lapses, provided that they have smoked no more
than 5 cigarettes since their agreed quit date.[16]
Secondary Outcome Measures
1. Self-reported, prolonged abstinence from smoking
between a quit date and 6 months afterwards with bio-
chemical validation by exhaled carbon monoxide meas-
urement at the 6 month point.
2. Self-reported, abstinence from smoking between a quit
date and 3 days afterwards (NB: this outcome is ascer-
tained by helpline counsellors, other outcomes ascer-
tained by a market research company)
3. Self-reported point prevalence abstinence from smok-
ing for at least 7 days, ascertained at 6 months with bio-
chemical validation
4. Self-reported point prevalence abstinence from smok-
ing for at least 7 days, ascertained at 6 months
5. Self-reported abstinence from smoking for at least three
months, ascertained at 6 months
6. Self-reported prolonged abstinence from smoking
between a quit date and 1 month
7. Self-reported point prevalence abstinence from smok-
ing for at least 7 days, ascertained at 1 months
8. Number of unsuccessful quit attempts lasting > 24 hrs,
reported at 6 months
Non smoking-related outcomes
Health status at 6 months (EQ5D)[17]
Use of other NHS smoking cessation interventions (e.g.
uptake of NHS Stop Smoking Services, use of other NRT
obtained from GP etc.)
Process measures/measures of intervention uptake
1. Number of successful counselling calls made to partici-
pants
2. Number (percentage) smokers who accept offer of NRT
vouchers
3. Number (percentage) smokers who are sent NRT from
pharmacy after receipt of vouchers
4. Number (percentage) smokers who report using NRT
Recruitment
The NHS Smoking Helpline is available to all smokers
who reside in England. We aim to inform all smokers who
call the NHS Smoking Helpline about the trial and to give
more information about it to those who express an inter-
est in participation, so that they can make an informed
decision. Web-hosted and print media information which
briefly informs people about the trial will be designed to
accompany existing information about the NHS SmokingTrials 2009, 10:26 http://www.trialsjournal.com/content/10/1/26
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PORTSSS Trial Participant Flow Chart Figure 1
PORTSSS Trial Participant Flow Chart.
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Helpline. This information will inform the reader that the
NHS Smoking Helpline is experimenting with ways of
providing support to smokers. Web based information
will include a patient information sheet that smokers will
be invited to download and read, prior to calling the NHS
Smoking Helpline.
When smokers telephone the NHS Smoking Helpline,
their call is initially taken by a non-counsellor telephonist
employed by Broadsystems, a company based in Bristol
UK. Broadsystems staff will not routinely give further
information about the trial to callers but will follow their
usual procedure which for smokers who want help with
stopping smoking, involves a mid-call transfer to speak
with one of a team of specialist smoking cessation advi-
sors who work for a company called Essentia. Any callers
who ask Broadsystems' telephonists for further informa-
tion about the trial will also be referred on to Essentia and
specially-trained Essentia smoking cessation advisors will
be responsible for obtaining informed consent from trial
participants. Essentia staff will use a scripted protocol to
verbally-inform interested callers about relevant aspects of
the trial and to invite them to participate. Any caller who,
after discussion, is not interested in the notion of trial par-
ticipation will receive normal NHS Smoking Helpline
care, which might involve registering for the Together Pro-
gramme (TP).
Completion of the scripted consent protocol will be
sequential, such that counsellors must confirm that initial
issues have been completely addressed before moving
onto subsequent ones. At the end of discussion about trial
enrolment, participants will be aware that their participa-
tion is voluntary, that if they decline to participate, their
care will not be affected and that they can withdraw from
the study at any time. Participants will also be made aware
that, in the event of their withdrawal from the trial, data
already collected would be used in analysis unless specific
permission/consent to use these data is also withdrawn.
All of these issues will be thoroughly dealt with by the
patient information sheet that can be accessed prior to
trial enrolment and which will be sent to all smokers who
decide to join the trial (see later).
Inclusion criteria
Participants are over 16 and will need to agree to i) receive
counselling ii) to set a quit within four weeks and iii) con-
sent to follow up.
Exclusion criteria
Telephonists will not enrol potential participants who are
not capable of giving informed consent or who have not
got access to a phone contact number to which calls can
be made by Essentia staff. The language of the usual Essen-
tia interview is English and it will not be possible to enrol
participants who cannot understand this.
Expected duration of participant participation
In both arms of the trial, participants will be offered tele-
phone counselling for up to 3 weeks after their agreed quit
date and participants who redeem NRT using vouchers
will be able to use this for up to 6 weeks.
Removal of participants from therapy or assessments
As is usual with this type of research, after randomisation
participants may choose not to use trial interventions (i.e.
they may ignore telephone calls or written materials
received in the post). Also a substantial proportion of par-
ticipants who do use trial interventions will not use these
as per protocol (e.g. they may decide not to participate in
a complete 'course' of phone calls). Such participants will
still be included in the final analysis which uses an inten-
tion to treat approach.
There is no risk to participants from behavioural counsel-
ling. NRT patches are available over the counter (OTC)
and, in 'NRT arms' a voucher for an OTC preparation will
be provided to quitline callers who want this and who
report no contraindications to their use. Upon voucher
redemption, NRT patches will be provided in the same
packaging as they are sold OTC and, in addition to any
advice on NRT that counselling interventions may
include, participants will be asked to read directions for
NRT use that are included with packaged OTC NRT. Par-
ticipants may resolve any questions that they have about
NRT use by discussion with a helpline counsellor or via
NRT patient information sheets and in the unlikely event
of residual uncertainty, they will be advised to discuss this
with their GP. The use of vouchers for NRT, issued by
smoking cessation counsellors mimics current clinical
practice, as NRT vouchers are distributed by NHS Stop
Smoking Service advisors in many parts of England. It is
anticipated that there will be no circumstances in which
the trial investigators will need to instruct participants to
discontinue NRT treatment, though counsellors advising
participants may need to recommend this. Additionally,
participants themselves may decide to discontinue treat-
ment after reading NRT usage instructions (e.g. if a rash
develops). In the rare eventuality of a major problem (e.g.
with the quality of supplied NRT), the research team
would be able to contact participants who had redeemed
vouchers and advise them. It should be noted that, in this
unlikely eventuality, participants would be easier to iden-
tify and contact than members of the public who had
bought NRT OTC.
Participants may be withdrawn from the trial at their own
request and, if they do so, will be made aware that this will
not affect their future care. Participants will also be madeTrials 2009, 10:26 http://www.trialsjournal.com/content/10/1/26
Page 6 of 12
(page number not for citation purposes)
aware, should they withdraw, the data collected to date
would only be erased and not used in the final analysis, if
they were to specifically request this.
Informed consent
All staff who obtain participant consent for the trial will
receive appropriate training and will be named in a trial
delegation log and, hence, authorised to do so. The
scripted protocol that trained Essentia staff use (see sec-
tion 'Recruitment', above), will ensure all important trial
issues which might concern the participant are discussed
and a copy of the PIS will be sent to participants. Verbal
consent onlywill be required and, to participate, quitline
callers must give explicit verbal consent to:
• permit routine data collected by Essentia to be used
for research
￿ telephone follow up by BMRB Social Research (a
commercial survey company)
￿ agree to a quit date with the Essentia counsellor/
telephonist, before being randomly allocated to one of
the trial treatment arms
￿ accept telephone calls from Essentia smoking cessa-
tion counsellors at a number of their choice and, if
necessary, allow counsellors to leave messages con-
cerning the reason for calling (i.e. smoking cessation
support) at this number
￿ having their personal details transferred by secure
electronic methods between Essentia, BMRB, a phar-
macy and the University of Nottingham research
team.
￿ potentially being asked to give an exhaled breath air
sample to a BMRB fieldworker
Immediately after the scripted consent protocol has been
completed and participant's consent obtained, the Essen-
tia counsellor who has conducted this process will gener-
ate three hard copies of a trial consent form. Database
restrictions will not permit form generation until the con-
sent protocol has been fully completed. Consent forms
will be automatically populated with the date and time
that consent was taken and also with an identifier or ini-
tials of the Essentia staff who obtained consent. This will
provide the trial manager or any other auditor with a clear
audit trail of who generated the consent form and will
also provide, if ever deemed necessary, the potential to
cross reference time of consent with that of the partici-
pants' call. Consent forms will also include participants'
names, addresses and telephone numbers. Copies will be:
i) received by the PORTSSS trial manager for research gov-
ernance purposes ii) stored within Essentia, so there is a
record of callers enrolled into the trial and iii) sent to par-
ticipants. The copy sent to participants will be accompa-
nied by a participant information sheet (PIS), with a letter
encouraging participants to read the PIS and think about
their decision to join the trial. Documentation will
include details of a contact point for participants who
have questions about trial participation.
The method of obtaining consent will allow this trial to
mimic normal quitline practice as quitline interventions
are usually delivered to callers during a single telephone
call at the time of their first contact. The proposed
approach is justifiable, given the minimal risk to trial par-
ticipants posed by trial interventions and the fact that, in
other contexts, these have all been demonstrated as effec-
tive for smoking cessation. The relatively light burden of
tasks imposed on participants and the fact that they will
effectively choose how much time and energy they devote
to trial participation also adds to the justifiability of the
consent process.
Most importantly, it would be very difficult, and perhaps
impossible, to answer the questions posed by the trial
without using the outlined approach to obtaining
informed consent. If consent forms signed by participants
were required, this would undoubtedly result in many
callers verbally agreeing to consent, but not subsequently
returning signed confirmation, despite still consenting to
participate. In this circumstance recruiting to a trial would
be difficult and providing robust experimental data about
the effectiveness of quitline interventions would be a chal-
lenge. Additionally, the external validity of trial findings
would be severely compromised and one would not be
able to say whether or not trial findings were actually rel-
evant to quitline practice. By obtaining verbal consent and
following this up with written information, some partici-
pants may decide after the initial recruitment discussion,
that, on balance, they do not wish to participate further.
As mentioned above, these non-participants will be given
information about how to contact the trial team to with-
draw consent, but even if they do not exercise this option,
they will still be able to ignore telephone or postal contact
from Essentia (delivering interventions) or the trial team/
BMRB (conducting follow up).
Randomization and Blinding
Level of blinding
Researchers conducting participants' follow up, the trial
manager and the trial management team will be blind to
treatment allocations. The trial statistician will also be
blinded to treatment allocation whilst the trial is progress-
ing, but, as is necessary with a factorial designs, will need
to identify treatment combinations during data analysis.
Trial participants will be aware of interventions that theyTrials 2009, 10:26 http://www.trialsjournal.com/content/10/1/26
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receive and counsellors giving trial treatments cannot be
blinded to these.
Randomisation process
All smokers who register with the 'Together Programme'
will be eligible for trial enrolment and Essentia counsel-
lors will randomise callers to one of four treatment groups
after obtaining their informed consent. A computer pro-
gramme will generate a random number sequence and,
after randomisation, participants will be issued with a
unique trial number and a code which corresponds to
their treatment and the first session of the allocated treat-
ment will be delivered. Any data that are exported for use
by the research team will have the treatment allocation
codes stripped out to maintain blinding. A key for the
numerical code will be held by the trial statistician who
will conduct the sole statistical analysis of trial data after
the trial has ended.
Baseline Measures
Consent will be obtained to use the following data items
which are routinely-obtained from all smokers who regis-
ter with the Together Programme:
birth date, gender postcode, employment status, ethnic
group, pregnancy, eligibility for free prescriptions, previ-
ous use of treatments for nicotine addiction, strength of
nicotine addiction as measured by the 'heaviness of smok-
ing index'[18] and quit attempts in the previous year.
Additionally, health status measured by EQ5D[17] will be
ascertained and participants will agree a quit date for stop-
ping smoking which is within four weeks. It is important
that the quit date is agreed before randomisation because
in a similar study, setting a quit date was not a criterion for
trial entry and approximately 43% of those enrolled did
not subsequently set one.[19] By requiring participants to
set quit dates, we will ensure that only the most motivated
smokers enrol into the trial and each participant will have
a definite event from which subsequent counselling ses-
sions and research follow ups can be timed.
Trial Groups
After randomisation, Essentia staff will be automatically
guided through the correct intervention for each partici-
pant via four on-screen templates. The Essentia database
will be configured so that only the template which corre-
sponds to the appropriate treatment allocation can be
used. Participants will be randomly allocated to either
usual care (i.e. control group, called the 'Together Pro-
gramme') which comprises reactive counselling or proac-
tive counselling (intervention 1) as described below.
Within these two groups there will also be random alloca-
tion of smokers to either being offered advice to obtain
nicotine addiction treatment (i.e. NRT, Varenicline or
Bupropion) from their general practitioner or local
NHSSSs (control) or an offer of a voucher which can be
redeemed at a pharmacy for a free supply of NRT (inter-
vention 2). The aim is to have four trial groups of equal
size.
Control – Together Programme
Usual Together Programme care involves offering smok-
ers support with smoking cessation via telephone, email,
written materials and/or text message and, if appropriate,
advising them to seek further support (potentially includ-
ing nicotine addiction therapies) from their local NHSSS
or general practitioner. After their first session, partici-
pants will be contacted by telephone (unless they prefer
email or text message) on their quit dates and at two days
and three weeks afterwards with brief motivational mes-
sages.
Intervention 1 – Proactive telephone counselling
Smokers will be offered usual "Together Programme"
written materials and modified email and text messages,
plus a programme of proactive telephone counselling fol-
lowing an agreed protocol, delivered by specially-trained
Essentia counsellors. After their initial counselling ses-
sion, participants will receive another call for counselling
prior to their quit date and also on the day that they stop
smoking itself. Subsequently participants will be eligible
to receive up to 4 further telephone counselling sessions
in the 3 weeks after their quit date. Earlier sessions will
help smokers to focus on and prepare for quitting and
later ones will focus on remaining smoke-free and pre-
venting relapse. This call pattern is based on a previously-
trialled, US quitline calls schedule and the weekly contacts
made after smokers' quit dates follow a similar frequency
to that used for face-to-face counselling by many NHSSSs.
During counselling and, if appropriate, smokers will be
advised to obtain further support (including, potentially,
nicotine addiction therapies) from their local NHSSSs or
general practitioners. Dr Andy McEwen (UCL – a protocol
author) will develop the intervention protocol and train
counsellors in proactive telephone counselling.
Intervention 2 – Provision of voucher for free NRT
During discussion of nicotine addiction treatments, call-
ers will be offered a voucher which can be redeemed at a
pharmacy for a cost free supply of NRT. Not all smokers
will choose to accept the voucher. For example, some
smokers might have previously used NRT, so that they do
not believe using this again is likely to be effective. Others
might prefer to try different treatments for nicotine addic-
tion which can be obtained from other sources.
For smokers who choose to accept the offer of an NRT
voucher, the Essentia counsellor will run through with
them a checklist of cautions to NRT. This checklist will beTrials 2009, 10:26 http://www.trialsjournal.com/content/10/1/26
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identical to that which is in the product information that
accompanies the over the counter (OTC) formulation of
NRT used in the trial. If callers report uncertainties about
any of the listed cautions applying to them, a voucher will
not be issued and they will be advised to discuss the
potential use of NRT with their GP. Vouchers will be gen-
erated electronically by the Essentia counsellor and sent to
the pharmacy team responsible for voucher redemption
and participants will be given a freephone number to call
for voucher redemption. Confirmation of this number
will sent by email, text or paper mail according to partici-
pants' preferences.
A 15 mg/16 hr transdermal nicotine patch which is avail-
able over the counter (OTC) and, hence, on the UK 'Gen-
eral Sales List' will be used and there are no specific
recommendations regarding their purchase or storage.
Although smokers in the UK can purchase such medica-
tion OTC, we propose that voucher redemption is over-
seen by a pharmacist to provide reassurance about trial
safety. NRT will be stored securely within a Glasgow phar-
macy and a secure system for recording i) when NRT has
been issued against any one voucher and ii) the batch
number of NRT sent to individuals will be used. The phar-
macy team will be part of the NHS Greater Glasgow and
Clyde's Public Heath Pharmacy Department.
Participants will be required to telephone the pharmacy
team to redeem their voucher and obtain NRT and they
will not be directly sent NRT without making such a
request. Participants' vouchers will make them eligible for
up to 6 weeks cost-free NRT treatment, supplied in
batches. All NRT packaging and instructions will be iden-
tical to that which has been approved for retail sale on a
General Sales License outside of pharmacies
In all trial groups, if smokers have not tried to stop on
their agreed quit date and they still wish to stop smoking,
a new (i.e. second) quit date will be agreed and the timing
of follow-ups will be tied to this point but no further re-
negotiation of quit dates will be permitted.
Compliance
This is a pragmatic trial, testing the delivery of interven-
tions in routine clinical use, using an intention to treat
analysis. In such studies it is usual for participants to have
variable compliance with interventions as their level of
engagement with these is self selected. Consequently,
uptake rates for interventions (e.g. the proportion of sub-
jects who redeem NRT vouchers) are amongst study out-
comes.
Frequency and duration of follow up
Interim follow up will occur at one month and final fol-
low up is at six months which is consistent with agreed
standards for the measurement of smoking cessation out-
comes in trials.[16] BMRB Social Research, a social
research company, will contact trial participants to obtain
follow up data. All participants will be asked about smok-
ing outcomes and health status (EQ5D) and up to 10
attempts will be made to contact participants before they
are categorised as 'lost to follow up'. Exhaled carbon mon-
oxide readings will be used to assess smoking status
amongst those smokers who report either i) continuous
abstinence from smoking cessation between their quit
date and 6 months, ii) 7 day (or longer) point prevalence
abstinence from smoking at 6 months. BMRB staff will
visit those smokers who report smoking cessation and
obtain exhaled CO samples. A cut off point of 10 ppm of
CO[16] in exhaled air will be used to differentiate
between smokers and non-smokers and three attempts at
CO validation will be made before any participant is
recorded as non-contactable.
Methods for protecting against bias
It will be impossible for Essentia staff delivering trial inter-
ventions to predict the outcome of randomisation, so
there should be no bias in the allocation of participants to
trial groups. All staff collecting follow-up information will
be blind to participants' treatment allocations. As partici-
pants cannot be blinded to their allocated intervention,
information about trial interventions will be carefully
worded to ensure that this does not contribute to higher
drop out rates in any one trial arm.
Statistical Methods
Sample Size and Justification
Sample size has been calculated to ensure that the trial is
adequately powered to detect meaningful differences in
the primary outcome measure (self report) and also in the
secondary outcome that involves biochemical validation
of this. A Cochrane review which compares, for smokers
who call quitlines, proactive telephone cessation counsel-
ling with very brief counselling and/or the provision of
smoking cessation materials only shows that proactive
counselling is effective (OR = 1.41, 95%CI 1.27 to
1.57)[13]. Furthermore, there is evidence that telephone
counselling is slightly more effective for motivated smok-
ers (i.e. those prepared to make a quit attempt) [OR (in
favour of motivated) 1.64, 95%CI 1.41 to 1.92] [13]. For
the PORTSSStrial, we will assume that proactive counsel-
ling (compared to reactive) will have a treatment effect
with an OR of 1.5. Given that we intend to recruit only
motivated smokers to this study, however, this is probably
a conservative assumption. The impact of telephone
counselling is likely to be increased by the offer of NRT
vouchers; two non-randomised US studies have shown
that offering NRT (or NRT vouchers) in addition to stand-
ard quitline increased cessation rates at 6 months by 80%
and 77% respectively[14,20]. A further randomised con-Trials 2009, 10:26 http://www.trialsjournal.com/content/10/1/26
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trolled trial with a factorial design assessed the impact of
three levels of intensity of telephone counselling and of
the offer of NRT and found an effect of NRT (OR = 1.58)
and no evidence of interaction between the effects of
counselling intensity and offer of NRT [21]. Conse-
quently, we will assume that the offer of NRT vouchers is
also associated with a treatment effect with an OR of 1.5,
i.e. that the size of this effect is similar to that for proactive
compared to reactive support, and that there will be no
interaction between the effects of these two interventions.
Predicting control group (reactive support, no offer of
NRT) quit rates for the PORTSSStrial is difficult because
no previous UK trials have specifically enrolled motivated
smokers (i.e. those who agree to make a quit attempt) and
also previous trials have relied solely on self-report meas-
ures of smoking behaviour. Recruiting motivated smokers
to PORTSSSis likely to increase quit rates at 6 months rel-
ative to previous UK trials, whereas using biochemical val-
idation of smoking behaviour will probably diminish the
number of cases for which primary outcome data is ascer-
tained, apparently decreasing PORTSSS's quit rates. How-
ever, two recent UK trials with similar control group
interventions to that proposed in PORTSSSreported, at 6
months, rates of prolonged abstinence from smoking for
at least 3 months of 11.6%[19] and 9.0%[22], respec-
tively. Consequently, we anticipate that in PORTSSS, self-
reported prolonged abstinence between smokers' quit
dates and their 6 month follow up will be 12% in the con-
trol group (reactive support, no offer of NRT). However,
our experience shows us that up to 1/3 of participants
who claim abstinence from smoking will not provide
saliva samples at follow up, so we reduce the expected
abstinence rate in the control group to 8%. In this factorial
design, assuming no interaction between treatments, the
comparison group for each treatment will comprise the
combination of the control group (who receive neither
treatment) and the group receiving only the other treat-
ment (see Figure 2). For example, if the odds ratio for each
treatment is 1.5 and the abstinence rate in the control is
8%, the comparison "group" would be expected to have
an abstinence rate of 10% (i.e. the average of 8% and
12%). In the absence of interaction, we plan two a priori
comparisons of the effect of each treatment versus the
appropriate comparison group, using p < 0.05 as the level
of statistical significance. Table 1 illustrates how varia-
tions in treatment effects and control group quit rates
might affect the sample size required to have 80% power
and 90% power (i.e. 90% chance of detecting a real effect
caused by the trial intervention). Remember that in this
table intervention and control groups are amalgamations
of trial arms such that NRT versus no NRT and proactive
versus reactive counselling are compared.
A further consideration is the increase in type 1 error aris-
ing as a result of including two primary treatment compar-
isons: proactive versus reactive counselling and NRT
versus no NRT. A more conservative approach would
adjust the p value to reflect the number of comparisons to
be made i.e. take p = 0.025 (0.05/2). Table 2 shows the
same power calculations as above using the more conserv-
ative p = 0.025.
To allow for this more conservative analysis we should
aim to recruit 3040 participants for 90% power. However,
if we aim to recruit 2576 we would have 90% power to
detect these differences as significant using a 5% signifi-
cance level, and at least 80% power to detect these differ-
ences as significant at the more conservative 2.5%
significance level.
Table 1: Sample sizes with different treatment effects and control group quit rates
Control (reactive support, no 
offer of NRT) group quit rate 
at 6 months (%)
Comparison "group" 
quit rate at 6 months 
(%)
Intervention "group" 
quit rate at 6 months 
(%)
Odds ratio for each treatment 
effect 
(proactive vs reactive, NRT vs 
no NRT)
Power Required sample size 
per group 
(total for 4 groups)
12%* 14% 18.6% 1.4 80% 536 (2142)
12%* 14.5% 20.3% 1.5 80% 355 (1420)
12% 14.5% 20.3% 1.5 90% 468 (1872)
8%** 9.5% 12.8% 1.4 80% 739 (2956)
8%** 10% 14% 1.5 80% 489 (1956)
8%** 10% 14% 1.5 90% 644 (2576)
* self report quit rates, ** biochemically validated quit rates
Final row figures (bold) show our most likely estimates for required sample sizes.Trials 2009, 10:26 http://www.trialsjournal.com/content/10/1/26
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Planned recruitment rate
It should be feasible to recruit 2576 smokers in approxi-
mately 6 months, though this can only be confirmed after
recruitment begins. In the first 6 months of 2007, 13,418
smokers registered with the Together Programme and the
trial will recruit from this pool of callers. In a previous
trial, only 28% of quit line callers who wanted counselling
also agreed to trial enrolment[19] and our necessary
requirement that participants agree to set a quit date could
further reduce enrolment and randomisation rates
amongst Together Programme registrations. Without
piloting, one cannot be entirely certain about the propor-
tion of callers who will agree to trial enrolment, but it is
likely that this will be sufficient for recruitment.
Potential problems with compliance
Participants randomised to receive proactive telephone
support may not actually answer or be available for many
of the calls that are made to them. If this situation were to
arise, then it could attenuate any differences between
interventions delivered to the control and intervention
groups, making it harder to detect an effect attributable to
the proactive call protocol. Additionally, participants who
register for the Together Programme are currently able to
telephone smoking cessation advisors whenever they wish
and if a large number make such calls were to be made,
this could further reduce differences between interven-
tions. Consequently, treatment protocols in the reactive
and proactive arms of the trial will need to be clearly
defined.
Expected rate of loss to follow-up
Previous UK studies have experienced losses to follow up
in the region of 30%[19,22] and we have planned for a
similar rate in this study, despite hoping to improve upon
this by using a specially-commissioned market research
company for follow up.
Statistical Analysis Methods
Primary analysis will be by intention to treat, presuming
continued smoking in those lost to follow-up. We will ini-
tially look for evidence of interaction between the effects
of the two treatment interventions (proactive versus reac-
tive support, and offer of NRT voucher versus no voucher
offer) using a test of interaction in a logistic regression
model. We do not anticipate interaction and presuming
there is none, we will compare those who were ran-
domised to proactive support (i.e. the combination of two
groups) with those randomised to reactive support, and
those offered of NRT with all those not offered NRT, using
two distinct chi-squared tests (see Figure 2 below).
Comparison Groups within PORTSSS Trial Figure 2
Comparison Groups within PORTSSS Trial.Trials 2009, 10:26 http://www.trialsjournal.com/content/10/1/26
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We will compare baseline characteristics of intervention
and usual care groups, adjusting for any baseline differ-
ences using multiple logistic regression. We will carry out
a sensitivity analysis to determine the influence of how
missing data at follow-up are handled on the study con-
clusions, varying the strength of association between
smoking status and 'missingness' (i.e. whether data are
missing), and allowing for individual, sampling and
imputation variation using multiple imputation.[23] We
will investigate whether or not socio-economic depriva-
tion (as measured by Townsend's score) is associated with
successful outcome by looking for effect modification
using a test for interaction to establish whether the effect
of each treatment is similar in more versus less deprived
groups. The data will be analysed at the end of the study
only; there is no need for interim analyses on safety
grounds, and having interim analyses alters the chance of
type 1 or type 2 error.
Procedures for missing, unused and spurious data
The standard method for dealing with loss to follow-up in
smoking cessation trials is to assume that those lost-to-fol-
low are continuing to smoke.[16] However, we will also
use methods of multiple imputation as suggested by
Hedeker[23] to explore the effect of assuming alternative
associations between 'missingness' and smoking status as
explained above.
Definition of populations analysed
As this is an intention to treat analysis, all participants
who cannot be contacted at follow up are assumed to be
still smoking and all randomised participants are
included in all analyses for trial outcomes. We will look
for effect modification by actual redemption of NRT
voucher and by the intensity of proactive counselling
received.
Health Economic Analysis
The economic analysis will be presented separately for the
within trial period (to summarise the observed evidence
in relation to cost-effectiveness) and for a projected life-
time cost-effectiveness. Within trial analyses will be pre-
sented both to test the underlying hypotheses and to
provide necessary parameter estimates for the lifetime
cost-effectiveness model. Resource use and cost data col-
lected and estimated within the trial will be used, together
with the primary outcome measure (cessation), to pro-
duce an estimate of the incremental 'cost per quitter' (that
is the additional cost of improving the quit rate). The
incremental cost per quality adjusted life year (QALY)
gained will also be estimated. It is likely that EQ5D will be
insensitive to change, therefore, the EQ5D data will be
more informative for the longer term modelling. Probabi-
listic sensitivity analysis will be undertaken to understand
the uncertainty surrounding the cost effectiveness esti-
mates[24].
A model, previously developed in a separate smoking ces-
sation project [25,26], which describes the long term
health benefits of quitting smoking in terms of QALYs
saved and potential reduced costs to the health service,
will then be analysed. Using this model, we will combine
trial outcome data and previously determined cost data
with estimates from the literature to extrapolate the cost
effectiveness at six months to one year, and then to a life-
time. The lifetime analysis will produce estimates of cost
per QALYs gained, thereby establishing the long term cost
effectiveness of proactive versus reactive smoking cessa-
tion support, with or without the offer of NRT vouchers.
Table 2: Sample sizes with different treatment effects and control group quit rates using conservative 'p' value (0.025)
Control (reactive support, no 
offer of NRT) group quit rate 
at 6 months (%)
Comparison "group" 
quit rate at 6 months 
(%)
Intervention "group" 
quit rate at 6 months 
(%)
Odds ratio for each treatment 
effect 
(proactive vs reactive, NRT vs 
no NRT)
Power Required sample size 
per group 
(total for 4 groups)
12%* 14% 18.6% 1.4 80% 644 (2576)
12%* 14.5% 20.3% 1.5 80% 426 (1704)
12% 14.5% 20.3% 1.5 90% 550 (2200)
8%** 9.5% 12.8% 1.4 80% 888 (3552)
8%** 10% 14% 1.5 80% 587 (2348)
8%** 10% 14% 1.5 90% 760 (3040)
* self report quit rates, ** biochemically validated quit rates
Final row figures (bold) show our most likely estimates for required sample sizes.Trials 2009, 10:26 http://www.trialsjournal.com/content/10/1/26
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Probabilistic sensitivity analysis will be used to character-
ise uncertainty in the parameters of the model driven by
estimates obtained from the trial. Finally, measuring
health status via EQ-5D will allow us to compare health-
related quality of life for trial participants with population
norms and allow us to undertake further sensitivity anal-
ysis within the long term model.
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